Base de dados : MEDLINE
Pesquisa : D03.132.225 [Categoria DeCS]
Referências encontradas : 12332 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1234 ir para página                         

  1 / 12332 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29274490
[Au] Autor:Ghawanmeh AA; Chong KF; Sarkar SM; Bakar MA; Othaman R; Khalid RM
[Ad] Endereço:Faculty of Industrial Sciences & Technology, University Malaysia Pahang, Gambang, 26300 Kuantan, Pahang, Malaysia. Electronic address: gh.just4chem@hotmail.com.
[Ti] Título:Colchicine prodrugs and codrugs: Chemistry and bioactivities.
[So] Source:Eur J Med Chem;144:229-242, 2018 Jan 20.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Antimitotic colchicine possesses low therapeutic index due to high toxicity effects in non-target cell. However, diverse colchicine analogs have been derivatized as intentions for toxicity reduction and structure-activity relationship (SAR) studying. Hybrid system of colchicine structure with nontoxic biofunctional compounds modified further affords a new entity in chemical structure with enhanced activity and selectivity. Moreover, nanocarrier formulation strategies have been used for colchicine delivery. This review paper focuses on colchicine nanoformulation, chemical synthesis of colchicine prodrugs and codrugs with different linkers, highlights linker chemical nature and biological activity of synthesized compounds. Additionally, classification of colchicine prodrugs based on type of conjugates is discussed, as biopolymers prodrugs, fluorescent prodrug, metal complexes prodrug, metal-labile prodrug and bioconjugate prodrug. Finally, we briefly summarized the biological importance of colchicine nanoformulation, colchicine prodrugs and codrugs.
[Mh] Termos MeSH primário: Colchicina/análogos & derivados
Colchicina/farmacologia
Pró-Fármacos/química
Pró-Fármacos/farmacologia
Moduladores de Tubulina/química
Moduladores de Tubulina/farmacologia
[Mh] Termos MeSH secundário: Animais
Desenho de Drogas
Seres Humanos
Mitose/efeitos dos fármacos
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Prodrugs); 0 (Tubulin Modulators); SML2Y3J35T (Colchicine)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171224
[St] Status:MEDLINE


  2 / 12332 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29402238
[Au] Autor:Tanyildiz B; Tezcan ME; Kandemir B; Günaydin NT; Göktas E; Tangilntiz A; Arsan AK
[Ad] Endereço:Dr. Lutfi Kirdar Kartal Education and Research Hospital, Department of Ophthalmology, Semsi Denizer Caddesi, E-5, 34890, Kartal Istanbul, Turkey. buraktanyildiz@yahoo.com.
[Ti] Título:Effect of oral Colchicine on Peripapillary retinal nerve fiber layer thickness in patients with familial Mediterranean fever.
[So] Source:BMC Ophthalmol;18(1):27, 2018 Feb 05.
[Is] ISSN:1471-2415
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The purpose of this study is to investigate whether oral colchicine has an effect on peripapillary retinal nerve fiber layer (pRNFL) thickness of familial Mediterranean fever (FMF) patients. METHODS: We conducted a cross sectional study by comparing pRNFL thickness of FMF patients on colchicine (treated group), newly diagnosed colchicine naïve FMF patients (untreated group) and healthy controls. The study included 66 FMF patients and 32 healthy control subjects. Treated FMF patients were grouped according to colchicine use, duration of use and dosage. pRNFL thickness of the patients and controls were measured by using optical coherence tomography and the measurements were compared. RESULTS: No statistically significant difference was found between the pRNFL thickness in untreated group, treated group and the healthy control group (all p > 0.05). No statistically significant difference was found between pRNFL thickness in the healthy control group and FMF patients grouped according to duration or dosage of colchicine use (all p > 0.05). CONCLUSIONS: According to our study, FMF and oral colchicine use had no statistically significant effect on pRNFL thickness.
[Mh] Termos MeSH primário: Colchicina/uso terapêutico
Febre Familiar do Mediterrâneo/tratamento farmacológico
Fibras Nervosas/efeitos dos fármacos
Células Ganglionares da Retina/efeitos dos fármacos
Moduladores de Tubulina/uso terapêutico
[Mh] Termos MeSH secundário: Administração Oral
Adulto
Estudos Transversais
Feminino
Seres Humanos
Pressão Intraocular
Masculino
Meia-Idade
Fibras Nervosas/patologia
Disco Óptico
Células Ganglionares da Retina/patologia
Tomografia de Coerência Óptica
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Tubulin Modulators); SML2Y3J35T (Colchicine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180207
[St] Status:MEDLINE
[do] DOI:10.1186/s12886-018-0698-1


  3 / 12332 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29293518
[Au] Autor:Poggio L; González GE
[Ad] Endereço:Instituto de Ecología, Genética y Evolución (IEGEBA, Consejo Nacional de Investigaciones Científicas y Técnicas-CONICET)-Laboratorio de Citogenética y Evolución (LaCyE), Departamento de Ecología, Genética y Evolución, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina.
[Ti] Título:Cytological diploidization of paleopolyploid genus Zea: Divergence between homoeologous chromosomes or activity of pairing regulator genes?
[So] Source:PLoS One;13(1):e0189644, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cytological diploidization process is different in autopolyploid and allopolyploid species. Colchicine applied at the onset of meiosis suppresses the effect of pairing regulator genes resulting multivalents formation in bivalent-forming species. Colchicine treated maizes (4x = 2n = 20, AmAmBmBm) showed up to 5IV, suggesting pairing between chromosomes from genomes homoeologous Am and Bm. In untreated individuals of the alloautooctoploid Zea perennis (8x = 2n = 40, ApApAp´Ap´Bp1Bp1Bp2Bp2) the most frequent configuration was 5IV+10II (formed by A and B genomes, respectively). The colchicine treated Z. perennis show up to 10IV revealing higher affinity within genomes A and B, but any homology among them. These results suggest the presence of a paring regulator locus (PrZ) in maize and Z. perennis, whose expression is suppressed by colchicine. It could be postulated that in Z. perennis, PrZ would affect independently the genomes A and B, being relevant the threshold of homology, the fidelity of pairing in each genomes and the ploidy level. Cytological analysis of the treated hexaploid hybrids (6x = 2n = 30), with Z. perennis as a parental, strongly suggests that PrZ is less effective in only one doses. This conclusion was reinforced by the homoeologous pairing observed in untreated dihaploid maizes, which showed up to 5II. Meiotic behaviour of individuals treated with different doses of colchicine allowed to postulate that PrZ affect the homoeologous association by controlling entire genomes (Am or Bm) rather than individual chromosomes. Based on cytological and statistical results it is possible to propose that the cytological diploidization in Zea species occurs by restriction of pairing between homoeologous chromosomes or by genetical divergence of the homoeologous chromosomes, as was observed in untreated Z. mays ssp. parviglumis. These are independent but complementary systems and could be acting jointly in the same nucleus.
[Mh] Termos MeSH primário: Cromossomos de Plantas
Diploide
Genes Reguladores
Zea mays/genética
[Mh] Termos MeSH secundário: Colchicina/administração & dosagem
Meiose
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
SML2Y3J35T (Colchicine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180103
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0189644


  4 / 12332 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29232311
[Au] Autor:Mooney JJ; Brady RO
[Ad] Endereço:From the Department of Psychiatry, Beth Israel Deaconess Medical Center; and Harvard Medical School, Boston, MA.
[Ti] Título:Lithium + Colchicine: A Potential Strategy to Reduce Pro-inflammatory Effects of Lithium Treatment.
[So] Source:J Clin Psychopharmacol;38(1):80-85, 2018 Feb.
[Is] ISSN:1533-712X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Rosenblat and McIntyre (Acta Psychiatr Scand. 2015;132: 180-191) propose that immune disorders are important mediators between bipolar disorders and medical comorbidities. Rosenblat et al (Bipolar Disord. 2016;18:89-101) present a meta-analysis showing that adjunctive anti-inflammatory agents could evoke moderate antidepressant responses in bipolar disorders. We propose using the anti-inflammatory drug colchicine to improve the long-term safety and efficacy of lithium treatment for bipolar disorders. METHODS: This report is based on searches of the PubMed and Web of Science databases. RESULTS: Bipolar disorders are associated with significant medical comorbidities such as hypertension, overweight/obesity, diabetes mellitus, metabolic syndrome, and arteriosclerosis, accompanied by enhanced release of pro-inflammatory markers during changes in mood state. During lithium therapy, granulocyte-colony stimulating factor, CD34+ hematopoietic stem/progenitor cells, and neutrophil elastase enter the circulation with activated neutrophils to promote the extravascular migration of activated neutrophils and enhance tissue inflammation. Concurrent treatment with lithium and low-dose colchicine could facilitate the responsiveness of bipolar patients to lithium by reducing leukocyte tissue emigration, the release of neutrophil elastase, and the release of leukocyte pro-inflammatory cytokines such as IL-1ß that are regulated by the NLRP3 inflammasome assembly complex. CONCLUSIONS: Concurrent therapy with lithium and low-dose colchicine could reduce complications involving leukocyte-mediated inflammatory states in bipolar patients and promote patient acceptance and responsiveness to lithium therapy.
[Mh] Termos MeSH primário: Colchicina/administração & dosagem
Inflamação/prevenção & controle
Compostos de Lítio/efeitos adversos
[Mh] Termos MeSH secundário: Anti-Inflamatórios/administração & dosagem
Anti-Inflamatórios/farmacologia
Transtorno Bipolar/complicações
Transtorno Bipolar/tratamento farmacológico
Colchicina/farmacologia
Citocinas
Relação Dose-Resposta a Droga
Seres Humanos
Inflamação/induzido quimicamente
Compostos de Lítio/administração & dosagem
Aceitação pelo Paciente de Cuidados de Saúde
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Cytokines); 0 (Lithium Compounds); SML2Y3J35T (Colchicine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE
[do] DOI:10.1097/JCP.0000000000000830


  5 / 12332 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29205989
[Au] Autor:Lehto J; Virolainen J
[Ti] Título:Postpericardiotomy syndrome.
[So] Source:Duodecim;133(4):411-6, 2017.
[Is] ISSN:0012-7183
[Cp] País de publicação:Finland
[La] Idioma:eng
[Ab] Resumo:Postpericardiotomy syndrome (PPS) is a common complication following cardiac surgery. In most cases it develops 2 to 3 weeks after the operation. An inflammatory reaction develops in the pericardium or pleural space with fever, chest pain and dyspnea as typical symptoms. The disease process is usually self-limiting. At present, the etiology is unknown, but an immunological mechanism is suspected as the cause of the disease. The incidence of PPS is essentially dependent on diagnostic criteria, patient group and type of operation. Treatment is carried out with anti-inflammatory analgesics, combined with colchicine in more severe cases.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/uso terapêutico
Colchicina/uso terapêutico
Síndrome Pós-Pericardiotomia/diagnóstico
Síndrome Pós-Pericardiotomia/tratamento farmacológico
Moduladores de Tubulina/uso terapêutico
[Mh] Termos MeSH secundário: Diagnóstico Diferencial
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Tubulin Modulators); SML2Y3J35T (Colchicine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE


  6 / 12332 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29205987
[Au] Autor:Lehtonen J
[Ti] Título:Recurrent pericarditis.
[So] Source:Duodecim;133(4):397-401, 2017.
[Is] ISSN:0012-7183
[Cp] País de publicação:Finland
[La] Idioma:eng
[Ab] Resumo:Recurrent pericarditis is the most common and problematic complication of acute pericarditis. After acute pericarditis, the pericarditis recurs in 20 to 50% of the patients. In most cases the etiology of pericarditis remains unclear, although it is generally thought to arise by an immunological mechanism. NSAID medication in combination with colchicine is the cornerstone of the treatment. Corticosteroids should be used mainly for those in whom the first-line drug treatment is not sufficient or first-line treatments are contraindicated.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/uso terapêutico
Colchicina/uso terapêutico
Pericardite/tratamento farmacológico
Pericardite/imunologia
Moduladores de Tubulina/uso terapêutico
[Mh] Termos MeSH secundário: Corticosteroides/uso terapêutico
Seres Humanos
Recidiva
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Tubulin Modulators); SML2Y3J35T (Colchicine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE


  7 / 12332 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29205986
[Au] Autor:Kytö V; Matti Niemelä M
[Ti] Título:Acute pericarditis.
[So] Source:Duodecim;133(4):391-6, 2017.
[Is] ISSN:0012-7183
[Cp] País de publicação:Finland
[La] Idioma:eng
[Ab] Resumo:Acute pericarditis is typically associated with a viral infection. Chest pain appearing in connection with or soon after the symptoms of infection is the characteristic symptom. Diagnosis is based on the recognition of two characteristic findings (pericardial chest pain, pericardial friction rub, new ECG changes or new pericardial effusion). Medication with an anti-inflammatory analgesic for 1 to 2 weeks is the first-line treatment. A longer course of colchicine is recommended for the prevention of recurrence of the disease. The use of glucocorticoids should be avoided due to the associated risk of recurrence. Exercise and physical activity are harmful during pericarditis.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/uso terapêutico
Colchicina/uso terapêutico
Pericardite/diagnóstico
Pericardite/tratamento farmacológico
Moduladores de Tubulina/uso terapêutico
[Mh] Termos MeSH secundário: Doença Aguda
Dor no Peito
Eletrocardiografia
Seres Humanos
Derrame Pericárdico/diagnóstico
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Tubulin Modulators); SML2Y3J35T (Colchicine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE


  8 / 12332 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28455804
[Au] Autor:Zhang C; Sun X; Xu SH; Yu BY; Zhang J
[Ad] Endereço:State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu, 210009, China.
[Ti] Título:Microbial Catalyzed Regio-Selective Demethylation of Colchicine by Streptomyces griseus ATCC 13273.
[So] Source:Appl Biochem Biotechnol;183(3):1026-1034, 2017 Nov.
[Is] ISSN:1559-0291
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Colchicinoids and their derivatives are of great importance in pharmaceutical applications, and colchicine is usually used as the first choice for the treatment of gout. To expand the structural diversities and clinical application of colchicinoids, many attempts have been established for the derivatives with better activity or less toxicity. Herein, in this paper, we report a direct microbial transformation of colchicine into 2-O-demethyl-colchicine (M1) and 3-O-demethl-colchicine (M2) by Streptomyces griseus ATCC 13273. It is noteworthy that when DMF was used as co-solvent, the yield of M1 and M2 could reach up to 51 and 31%, respectively. All the structures of the metabolites were elucidated unambiguously by ESI-MS, H-NMR, C-NMR, and 2D-NMR spectroscopy.
[Mh] Termos MeSH primário: Biocatálise
Colchicina/química
Colchicina/metabolismo
Poluentes Ambientais/química
Poluentes Ambientais/metabolismo
Streptomyces griseus/metabolismo
[Mh] Termos MeSH secundário: Biotransformação
Metilação
Estereoisomerismo
Especificidade por Substrato
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Environmental Pollutants); SML2Y3J35T (Colchicine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE
[do] DOI:10.1007/s12010-017-2480-x


  9 / 12332 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29061810
[Au] Autor:Cho JH; Joo YH; Shin EY; Park EJ; Kim MS
[Ad] Endereço:Department of Otolaryngology-Head and Neck Surgery, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
[Ti] Título:Anticancer Effects of Colchicine on Hypopharyngeal Cancer.
[So] Source:Anticancer Res;37(11):6269-6280, 2017 11.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:Colchicine is an alkaloid widely used for the treatment of inflammatory diseases, such as gout. It suppresses cell division by inhibiting mitosis. We investigated the anticancer effects of colchicine on human hypopharyngeal cancer cells and the mechanisms underlying its anticancer effects. XTT cell proliferation assay showed that colchicine inhibited the growth and proliferation of human hypopharyngeal cancer cells (FaDu and SNU1041) in a dose- and time-dependent manner. Colchicine also inhibited the migration, invasion, and adhesion of hypopharyngeal cancer cells in a dose-dependent manner. The levels of mRNA expression and activity of matrix metalloproteinase-9 (MMP9) and urokinase-type plasminogen activator (uPA) decreased after treatment with colchicine. Further investigation revealed that colchicine inhibited the phosphorylation of the FAK/SRC complex and paxillin. Tumor volume ratios in colchicine-treated mice (0.1 mg/kg, every 2 days for 14 days) increased less than in control mice. To our knowledge, this is the first report showing that colchicine can suppress cell invasion, migration, and adhesion through reduced expression of MMP9, the uPA system, and the FAK/SRC complex. Colchicine has the potential to prevent disease progression in hypopharyngeal cancer and may have application as an adjunctive treatment.
[Mh] Termos MeSH primário: Antineoplásicos/administração & dosagem
Colchicina/administração & dosagem
Neoplasias Hipofaríngeas/tratamento farmacológico
Metaloproteinase 9 da Matriz/genética
Ativador de Plasminogênio Tipo Uroquinase/genética
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/farmacologia
Linhagem Celular Tumoral
Movimento Celular/efeitos dos fármacos
Proliferação Celular/efeitos dos fármacos
Sobrevivência Celular/efeitos dos fármacos
Colchicina/farmacologia
Relação Dose-Resposta a Droga
Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos
Seres Humanos
Neoplasias Hipofaríngeas/genética
Neoplasias Hipofaríngeas/metabolismo
Metaloproteinase 9 da Matriz/metabolismo
Camundongos
Invasividade Neoplásica
Ativador de Plasminogênio Tipo Uroquinase/metabolismo
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); EC 3.4.21.73 (Urokinase-Type Plasminogen Activator); EC 3.4.24.35 (MMP9 protein, human); EC 3.4.24.35 (Matrix Metalloproteinase 9); SML2Y3J35T (Colchicine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171025
[St] Status:MEDLINE


  10 / 12332 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28987498
[Au] Autor:Bahrani S; Ghaedi M; Dashtian K; Ostovan A; Mansoorkhani MJK; Salehi A
[Ad] Endereço:Departmentof chemistry, Yasouj University, Yasouj, 75918-74831, Iran.
[Ti] Título:MOF-5(Zn)-Fe O nanocomposite based magnetic solid-phase microextraction followed by HPLC-UV for efficient enrichment of colchicine in root of colchicium extracts and plasma samples.
[So] Source:J Chromatogr B Analyt Technol Biomed Life Sci;1067:45-52, 2017 Nov 01.
[Is] ISSN:1873-376X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:In present work, facile method is developed for determination of colchicine in human plasma sample, autumn and spring root of colchicium extracts by ultrasound assisted dispersive magnetic solid phase microextraction followed by HPLC-UV method (UAD-MSPME-HPLC-UV). Magnetic (Fe O -nanoparticles) metal organic framework-5, (MOF-5(Zn)-Fe O NPs) was synthesized by dispersing MOF-5 and Fe(NO ) .9H O in ethylene glycol (as capping agent) and NaOH (pH adjustment agent) by hydrothermal method. The prepared sorbent was characterized via XRD and SEM analysis and applied as magnetic solid phase in UAD-MSPME-HPLC-UV method. In this method, colchicine molecules were sorbed on MOF-5(Zn)-Fe O NPs sorbent by various mechanisms like ion exchange, hydrogen bonding and electrostatic, á´¨-á´¨, hard-hard and dipole-ion interaction followed by exposing sonication waves as incremental mass transfer agent and then the sorbent was separated from the sample matrix by an external magnetic fields. Subsequently, accumulated colchicine were eluted by small volume of desorption organic solvent. Influence of operational variables such as MOF-5(Zn)-Fe O NPs mass, volume of extracting solvent and sonication time on response property (recovery) were studied and optimized by central composite design (CCD) combined with desirability function (DF) approach. Under optimum condition, the method has wide linear calibration rang (0.5-1700ngmL ) with reasonable detection limit (0.13ngmL ) and R =0.9971. Finally, the UAD-MSPME-HPLC-UV method was successfully applied for determination of colchicine autumn and spring root of colchicium extracts and plasma samples.
[Mh] Termos MeSH primário: Cromatografia Líquida de Alta Pressão/métodos
Colchicina
Colchicum/química
Nanocompostos/química
Extratos Vegetais/química
Microextração em Fase Sólida/métodos
[Mh] Termos MeSH secundário: Colchicina/análise
Colchicina/química
Colchicina/isolamento & purificação
Óxido Ferroso-Férrico/química
Concentração de Íons de Hidrogênio
Limite de Detecção
Modelos Lineares
Raízes de Plantas/química
Reprodutibilidade dos Testes
Compostos de Zinco/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Plant Extracts); 0 (Zinc Compounds); SML2Y3J35T (Colchicine); XM0M87F357 (Ferrosoferric Oxide)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171009
[St] Status:MEDLINE



página 1 de 1234 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde